These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25894088)

  • 21. Bioequivalence studies with anti-TNF biosimilars.
    Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F
    Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial design in biosimilar drug development.
    Dranitsaris G; Dorward K; Hatzimichael E; Amir E
    Invest New Drugs; 2013 Apr; 31(2):479-87. PubMed ID: 23161336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interchangeability of Biosimilars: A European Perspective.
    Kurki P; van Aerts L; Wolff-Holz E; Giezen T; Skibeli V; Weise M
    BioDrugs; 2017 Apr; 31(2):83-91. PubMed ID: 28120313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials for authorized biosimilars in the European Union: a systematic review.
    Mielke J; Jilma B; Koenig F; Jones B
    Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars in psoriasis: what can we expect?
    Radtke MA; Augustin M
    J Dtsch Dermatol Ges; 2014 Apr; 12(4):306-12. PubMed ID: 24698590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency estimator for assessing of follow-on biologics.
    Lu Y; Zhang ZZ; Chow SC
    J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the interchangeability of biologic drug products.
    Endrenyi L; Chang C; Chow SC; Tothfalusi L
    Stat Med; 2013 Feb; 32(3):434-41. PubMed ID: 22911936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biosimilars in rheumatology. Development and results of clinical trials].
    Alten R
    Z Rheumatol; 2015 Oct; 74(8):682-8. PubMed ID: 26347121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.